Open Orphan ‘Venn will deliver significant additional revenue’, announces contract extension with Carna Biosciences

Open Orphan

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract renewal with Carna Biosciences, Inc., extending its integrated drug development consultancy services with Venn Life Sciences, part of Open Orphan plc.

Executive Chairman Cathal Friel told DirectorsTalk Interviews, “We are announcing the signing of a contract extension with Carna Biosciences Inc by our Venn team in the Netherlands which will deliver significant additional revenue for Venn for the coming 12 months and is a clear sign of how we are growing and expanding the Venn business substantially. Carna is a clinical-stage biopharmaceutical companywhich focuses on the discovery and development of innovative therapies to treat serious unmet medical needs. Venn will be providing Chemistry, Manufacturing & Control (CMC), Non-Clinical, Clinical and also Regulatory consultancy services to this client for two of their leading drug development programmes.  

Venn and Carna have built up a good working relationship over several years and this extension further demonstrates our ability to collaborate successfully with our clients and provide a service that results in repeat business.”

Carna Biosciences is a clinical-stage biopharmaceutical company which focuses on the discovery and development of innovative therapies to treat serious unmet medical needs, focusing on small molecule drugs. The renewal of this contract is expected to deliver significant revenue for Venn over the next twelve months.

The Venn team in the Breda office in the Netherlands, will provide Chemistry, Manufacturing & Control (CMC), Non-Clinical, Clinical and Regulatory consultancy services to this client for two of the client’s leading development programmes. This successful collaboration has been extended until the end of December 2021.

Cathal Friel, Executive Chairman of Open Orphan, said: “The extension of this contract further demonstrates our ability to collaborate successfully with our clients and provide a service that results in repeat business. Venn and Carna have built up a good working relationship over a period of several years where both parties closely collaborated on drug development planning and its execution through consultancy services contracts. We look forward to delivering this contract for Carna in the year ahead.”

Masaaki Sawa, Ph.D., Chief Scientific Officer and Head of Research and Development at Carna Biosciences, said: “The partnership with Venn Life Sciences complements our clinical development team and underlines our commitment to become a clinical stage company. By continuing the collaboration with the Venn team, we will accelerate our drug development.”

You might also enjoy reading  Open Orphan win £6.2m Influenza human challenge study contract
Find more news, interviews, share price & company profile here for:
Open Orphan plc

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit
Find more news, interviews, share price & company profile here for:
Open Orphan plc

AIM All Share Index